O Shaughnessy Asset Management LLC Raises Stake in Becton, Dickinson and Company $BDX

O Shaughnessy Asset Management LLC lifted its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 27.9% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 44,703 shares of the medical instruments supplier’s stock after purchasing an additional 9,758 shares during the quarter. O Shaughnessy Asset Management LLC’s holdings in Becton, Dickinson and Company were worth $8,676,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Imprint Wealth LLC purchased a new stake in shares of Becton, Dickinson and Company during the 3rd quarter worth about $25,000. Steph & Co. grew its holdings in shares of Becton, Dickinson and Company by 95.6% during the 4th quarter. Steph & Co. now owns 133 shares of the medical instruments supplier’s stock worth $26,000 after purchasing an additional 65 shares during the period. Accredited Wealth Management LLC grew its holdings in shares of Becton, Dickinson and Company by 77.8% during the 3rd quarter. Accredited Wealth Management LLC now owns 160 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 70 shares during the period. WPG Advisers LLC grew its holdings in shares of Becton, Dickinson and Company by 64.2% during the 4th quarter. WPG Advisers LLC now owns 156 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 61 shares during the period. Finally, Kohmann Bosshard Financial Services LLC purchased a new stake in shares of Becton, Dickinson and Company during the 4th quarter worth about $32,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Insider Activity

In other Becton, Dickinson and Company news, CEO Thomas E. Polen, Jr. sold 2,764 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $146.35, for a total value of $404,511.40. Following the transaction, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at $16,122,355.05. This represents a 2.45% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 2,913 shares of company stock valued at $426,806. Corporate insiders own 0.40% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. Stifel Nicolaus decreased their target price on Becton, Dickinson and Company from $215.00 to $175.00 in a report on Thursday, May 7th. Zacks Research upgraded Becton, Dickinson and Company from a “strong sell” rating to a “hold” rating in a report on Friday, April 10th. Wells Fargo & Company upped their price target on Becton, Dickinson and Company from $157.00 to $161.00 and gave the stock an “equal weight” rating in a report on Friday, May 8th. Weiss Ratings cut Becton, Dickinson and Company from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, May 11th. Finally, TD Cowen decreased their price target on Becton, Dickinson and Company from $189.00 to $163.00 and set a “hold” rating for the company in a report on Monday, May 4th. Seven equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $183.64.

Becton, Dickinson and Company Stock Down 2.6%

NYSE BDX opened at $148.14 on Thursday. The stock has a market cap of $40.82 billion, a PE ratio of 37.50, a P/E/G ratio of 10.76 and a beta of 0.22. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $187.35. The business has a 50 day moving average price of $150.40 and a two-hundred day moving average price of $174.56. The company has a quick ratio of 0.55, a current ratio of 0.94 and a debt-to-equity ratio of 0.62.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share for the quarter, topping analysts’ consensus estimates of $2.77 by $0.13. The firm had revenue of $4.71 billion during the quarter, compared to analysts’ expectations of $4.67 billion. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.Becton, Dickinson and Company’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.35 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. As a group, sell-side analysts predict that Becton, Dickinson and Company will post 12.61 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 30th. Shareholders of record on Tuesday, June 9th will be given a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date of this dividend is Tuesday, June 9th. Becton, Dickinson and Company’s dividend payout ratio is presently 106.33%.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.